Pharmacogenetics of sulfonylurea-induced hypoglycemia in type 2 diabetes patients: The SUCLINGEN study
Document Type
Article
Publication Date
11-1-2021
Abstract
Aim: This study investigated the incidence of sulfonylurea-induced hypoglycemia and its predictors in Type 2 diabetes (T2D) patients. Patients & methods: In this prospective, observational study, T2D patients on maximal sulfonylurea-metformin therapy >1 year were enrolled. Hypoglycemia was defined as having symptoms or a blood glucose level Results: Of the 401 patients, 120 (29.9%) developed sulfonylurea-induced hypoglycemia during the 12-month follow-up. The ABCC8 rs757110, KCNJ11 rs5219, CDKAL1 rs7756992 and KCNQ1 rs2237892 gene polymorphisms were not associated with sulfonylurea-induced hypoglycemia (p > 0.05). Prior history of hypoglycemia admission (odds ratio = 16.44; 95% CI: 1.74-154.33, p = 0.014) independently predicted its risk. Conclusion: Sulfonylurea-treated T2D patients who experienced severe hypoglycemia are at increased risk of future hypoglycemia episodes.
Keywords
ABCC8 rs757110 polymorphism, CDKAL1 rs7756992 polymorphism, hypoglycemia, KCNJ11 rs5219 polymorphism, KCNQ1 rs2237892 polymorphism, Sulfonylurea
Divisions
fac_med
Funders
Universiti Malaya (RP024-14HTM),Universiti Malaya (PG056-2014A)
Publication Title
Pharmacogenomics
Volume
22
Issue
16
Publisher
Future Medicine Ltd
Publisher Location
UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND